Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Receivables for 12 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 84.94% to $18.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.4 million through Dec 2025, down 84.94% year-over-year, with the annual reading at $18.4 million for FY2025, 84.94% down from the prior year.
  • Receivables hit $18.4 million in Q4 2025 for Coherus Oncology, down from $250.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $313.6 million in Q2 2024 to a low of $18.4 million in Q4 2025.
  • Historically, Receivables has averaged $153.3 million across 5 years, with a median of $129.7 million in 2021.
  • Biggest five-year swings in Receivables: surged 180.07% in 2024 and later plummeted 84.94% in 2025.
  • Year by year, Receivables stood at $123.0 million in 2021, then dropped by 10.61% to $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then tumbled by 53.04% to $122.3 million in 2024, then tumbled by 84.94% to $18.4 million in 2025.
  • Business Quant data shows Receivables for CHRS at $18.4 million in Q4 2025, $250.5 million in Q3 2025, and $119.6 million in Q2 2025.